Comparative Pharmacology
Head-to-head clinical analysis: PYLORI CHEK BREATH TEST versus R GENE 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PYLORI CHEK BREATH TEST versus R GENE 10.
PYLORI-CHEK BREATH TEST vs R-GENE 10
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Urea labeled with 13C is hydrolyzed by urease enzyme produced by Helicobacter pylori, producing 13CO2 which is exhaled and detected in breath.
Arginine is a semi-essential amino acid that serves as a substrate for nitric oxide (NO) synthesis via nitric oxide synthase (NOS), leading to vasodilation. It also stimulates growth hormone release and is involved in the urea cycle for ammonia detoxification.
Adults: 75 mg of 13C-urea dissolved in 75 mL of water, administered orally as a single dose. Breath samples collected at baseline and 30 minutes post-dose.
10 mg intravenously over 1-2 minutes, once daily for 5 days, repeat course after 2-3 weeks if needed.
None Documented
None Documented
The elimination half-life of 13C-urea is approximately 0.5–1 hour in patients with normal renal function, reflecting rapid renal clearance. In severe renal impairment, half-life may be prolonged up to 7–10 hours.
Terminal elimination half-life is 2-4 hours (mean 3 hours) in adults with normal renal function; prolonged to 8-18 hours in renal impairment.
13C-urea is excreted renally as intact urea (approximately 85%) and as 13CO2 in breath (approximately 15%). Fecal elimination is negligible. In renal impairment, breath 13CO2 excretion may increase as renal clearance decreases.
Primarily renal (approximately 80-90% unchanged). Biliary/fecal elimination accounts for <5%.
Category C
Category C
Diagnostic Agent
Diagnostic Agent